Long-acting PYY₃ _-36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies.

ABSTRACT:

Objective

The hormone peptide YY (PYY; cleaved into Y₂-selective form PYY_3-36) is an attractive candidate for use as a complementary pharmacotherapy for obesity along with glucagon-like peptide-1 (GLP-1) receptor agonists. This series of studies investigated a novel long-acting PYY_3-36 analogue (PYY1875) alone and as an add-on to semaglutide for treatment of obesity.

Methods

Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.

Results

PYY1875 induced additional body weight loss in semagl

SUBMITTER: Wulff BS 

PROVIDER: S-EPMC12304869 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature